Anika Therapeutics (ANIK) Common Equity (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Common Equity data on file, last reported at $133.9 million in Q1 2026.

• On a quarterly basis, Common Equity fell 9.77% year-over-year to $133.9 million in Q1 2026; TTM through Mar 2026 was $133.9 million, a 9.77% decrease from a year earlier, with the FY2025 full-year figure at $143.5 million, down 6.83% from the prior year.
• Common Equity for Q1 2026 stood at $133.9 million, down from $143.5 million in the prior quarter.
• Over the last five years, Common Equity for ANIK reached as high as $286.2 million in Q2 2022 and fell as low as $133.9 million in Q1 2026.
• Historically, Common Equity has averaged $214.7 million across 5 years, with a median of $210.3 million in 2024.
• Across the five-year window, Common Equity advanced 3.3% in 2022 and slumped 33.5% in 2024, its largest moves.
• Year by year, Common Equity stood at $285.6 million in 2022, then dropped by 25.67% to $212.3 million in 2023, then retreated by 27.45% to $154.0 million in 2024, then retreated by 6.83% to $143.5 million in 2025, then fell by 6.67% to $133.9 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $133.9 million in Q1 2026, $143.5 million in Q4 2025, and $146.8 million in Q3 2025.